Vienna Team Saves Patient After 12 Years on Transplant List

A man who spent over a decade waiting for a kidney transplant with no hope in sight is now living dialysis-free, thanks to a medical breakthrough from researchers in Vienna.

The 37-year-old patient had developed severe antibody reactions against potential donor organs after two previous transplants failed. His immune system had become so sensitized that doctors calculated his chance of ever finding a compatible kidney at zero percent. He remained on dialysis while his health slowly declined, trapped in what seemed like an impossible situation.

Then researchers at the Medical University of Vienna tried something new. They turned to teclistamab, a drug normally used to treat blood cancer, to see if it could help reduce the antibodies blocking his transplant eligibility.

The treatment worked better than anyone expected. Over 31 weeks, the cancer drug systematically eliminated the cells producing antibodies against donor organs. Gradually, kidney tissue that his immune system previously rejected became acceptable matches.

A suitable donor organ was finally found and successfully transplanted. Today, the patient is thriving with excellent kidney function and no longer needs dialysis treatments that once dominated his life.

The Ripple Effect

This breakthrough could transform outcomes for thousands of patients facing similar odds. Between 20 and 30 percent of people waiting for kidney transplants struggle with significant antibody sensitization, and some have no realistic chance of receiving a compatible organ under current treatment options.

Existing methods to reduce antibodies before transplants only work for short periods and show limited effectiveness. This new approach directly targets antibody production at its source, creating sustained reduction over longer timeframes.

Lead researcher Georg Böhmig believes this could represent a paradigm shift in transplant medicine. The treatment strategy might also work for organ transplants from genetically modified pigs and could extend to heart transplants or post-transplant rejection episodes.

The research team published their findings in the New England Journal of Medicine and is already planning larger clinical trials to systematically study the benefits and risks. If those studies confirm these early results, thousands of patients currently considered untransplantable might finally have hope for a second chance at life without dialysis.